Full-Time

Design Quality Assurance Engineer

LGC Group

LGC Group

1,001-5,000 employees

Sells oligos, probes, primers, viral materials

No salary listed

Limerick, Ireland

In Person

On-site role; Ballina, County Tipperary; no remote work.

Bachelor's

Category
QA & Testing (1)
Required Skills
Risk Management

Get referred to LGC Group

See people who can refer or advise you

Requirements
  • Educated to a minimum of degree level in Science/Engineering/QA or related discipline or equivalent
  • A minimum of 2 years practical experience required in a quality function or equivalent
  • Thorough knowledge of the applicable regulatory requirements
  • Knowledge of international regulatory requirements relevant to the business
Responsibilities
  • Responsible for supporting the Design Control process and ensuring that Design History Files comply with Technopath Clinical Diagnostic (TCD) policies/procedures and applicable regulatory requirements
  • Act as the Quality representative on Design Control projects from project initiation through to product launch to ensure compliance to applicable procedures and standards
  • Manage and lead the change control process by liaising with impacted areas to ensure timely and compliant implementation and completion
  • Work in collaboration with R&D, Labelling, Operations, Validation, Business Development and Supply chain on design control and change control projects
  • Review and approve all process validation documentation inclusive of plans, protocols and reports ensuring compliance to applicable procedures and standards
  • Responsible for creation and maintenance of Risk Management Files for each product
  • Facilitate process and design failure mode and effects analysis meetings
  • Responsible for maintaining Design Control and R&D procedures to ensure compliance to regulatory or standard requirements
  • Perform Post Market Surveillance activities per the requirements of the applicable procedures and regulations
  • Liaise with external customers on change requests
  • Provide training and guidance to staff on the requirements of the design control and change control process in TCD
  • As required perform internal audits to ensure compliance of TCDs quality management system to the requirements of all applicable requirements
  • Perform other related duties as prescribed by the Global Design QA and Risk Manager and Director of Quality Assurance
Desired Qualifications
  • Knowledge desirable in relation to risk management; ideally in the IVD or Medical Device industry

LGC Group provides life-sciences tools and services worldwide, including oligo components, probes, primers, recombinant viral materials, and proficiency-testing schemes for food safety. Its products support vaccine development, diagnostics, and therapies through mass spectrometry, immunoassays, and nucleic acid chemistry. It differentiates itself with a broad catalog of high-quality tools plus global proficiency-testing services and a wide customer base across diagnostics, healthcare, and pharma. Its goal is to improve healthcare outcomes and help create safer vaccines and treatments by delivering reliable tools and quality services.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

London, United Kingdom

Founded

1841

Get referred to LGC Group

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • LGC bought ChromaDex Reference Standards on 26 February 2026, expanding North American reach.
  • LGC opened its CAD$100 million Vaughan synthesis center in 2026, increasing chemistry capacity.
  • DiaMex integration keeps widening LGC's clinical diagnostics portfolio after the 4 December 2024 deal.

What critics are saying

  • S&P kept LGC at B-/Stable in 2025, citing 12x-13x leverage.
  • Cinven and Astorg own LGC, keeping exit pressure and debt servicing overhang high.
  • Thermo Fisher, Bio-Rad, and Randox squeeze margins in controls, standards, and diagnostics.
  • If 2026 integration or capex disappoints, lenders force asset sales or refinancing.

What makes LGC Group unique

  • LGC's 3,000-plus ChromaDex standards deepens its reference-material moat across regulated labs.
  • LGC Axolabs Berlin adds cGMP oligonucleotide API manufacturing, spanning discovery through commercial supply.
  • LGC's National Laboratory role and proficiency-testing franchises embed it in compliance workflows.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

-8%

1 year growth

-8%

2 year growth

-8%
LNEG - Laboratório Nacional de Energia e Geologia
Jul 17th, 2026
LNEG and LGC are organising an international workshop on ocean-inspired strategies at SEA TECH WEEK 2026.

LNEG and LGC are organising an international workshop on ocean-inspired strategies at SEA TECH WEEK 2026. Published on 17 July, 2026 Updated on 17 July, 2026 The National Laboratory for Energy and Geology (LNEG, Lisbon) and the Laboratoire de Génie Chimique (LGC, Toulouse) are organising, as part of SEA TECH WEEK 2026, the workshop 'Marine-Inspired Strategies for Enhancing Materials Durability' (STW40), to be held on the morning of 8 October in Brest, France. SEA TECH WEEK is one of the leading international events dedicated to maritime science and technology, bringing together experts, researchers and companies from across Europe in Brest between 6 and 8 October to discuss innovation in the service of the ocean. This year, Portugal is the guest country for the event, which guarantees free registration for Portuguese participants. The STW40 workshop, one of the workshops proposed and selected for inclusion in the event's official programme, forms part of the ALGAPROTEC project (LGC & LNEG), a bilateral cooperation initiative between France and Portugal, funded by the CNRS IRP programme (International Research Project).

LGC Group
Feb 26th, 2026
LGC Group strengthens its reference material portfolio and North American reach with the acquisition of the ChromaDex Reference Standards business

LGC Group strengthens its reference material portfolio and North American reach with the acquisition of the ChromaDex Reference Standards business. The acquisition further enhances LGC's ability to support pharmaceutical, food, and testing laboratories with trusted reference materials that underpin safety, quality, and regulatory confidence. London, UK, 26 February 2026. LGC Group, a global leader in life sciences, diagnostics, and analytical solutions, today announced the acquisition of the ChromaDex Reference Standards portfolio from Niagen Bioscience (NASDAQ: NAGE). The acquisition expands LGC's reference materials offering and strengthens its commercial reach across North America. The acquisition brings an established portfolio of phytochemical reference materials for the dietary supplements industry into LGC, enabling direct engagement with a broad base of laboratory customers and strengthening LGC's ability to support pharmaceutical companies, testing laboratories, and food producers operating in regulated markets. Bruno Rossi, EVP & General Manager, LGC Standards, said: "The ChromaDex standards portfolio further enhances LGC's ability to support our pharmaceutical customers, testing laboratories, and food producers. Building on LGC's position as a world leader in reference materials and analytical standards, this acquisition expands our North American commercial reach and further supports customers in generating reliable data that safeguards product integrity and confidence across global supply chains." For over 25 years, the ChromaDex Reference Standards portfolio has been built on deep expertise in phytochemical characterisation and analytical verification. The portfolio includes over 3,000 phytochemical reference materials, spanning major classes such as alkaloids, flavonoids, terpenes, carotenoids, organic acids, stilbenoids, vitamins, and select botanicals and plant-based compounds. These materials are widely used to support ingredient verification, method development, authenticity testing, contamination detection, and routine quality control across complex global supply chains. Rob Fried, CEO of Niagen Bioscience, remarked, "This transaction reflects our disciplined focus on what we do best - advancing NAD+ science and delivering clinically proven, patented Niagen(R) solutions across consumer and clinical channels. Selling Reference Standards to LGC is a meaningful step in simplifying our business and ensuring we are allocating capital and talent toward the highest-impact opportunities for shareholders." The acquisition of the ChromaDex Reference Standards portfolio demonstrates LGC's commitment to providing trusted reference materials and measurement solutions that reinforce product safety, quality, and regulatory confidence, advancing its mission of Science for a Safer World. LGC is a global leader in life sciences, diagnostics, and analytical solutions. LGC Group work with partners around the world to address some of society's most important challenges, from diagnosing disease and enabling new treatments to supporting food security and protecting public health. Its science supports discovery, enables better health outcomes and helps safeguard the integrity of food, water, medicines and the environment. Every day, LGC Group provide the components, standards and services that laboratories, manufacturers and regulators rely on to make confident, evidence-based decisions. With operations in 14 countries and more than 180 years of scientific expertise, its work supports public health and sustainability at a global scale. From improving the accuracy of medical testing and verifying the safety of food products, to helping scientists develop the next generation of medicines, its solutions are trusted by customers in more than 170 countries. For further information please contact: Customer contact: Richard Pembrey Sales Director, LGC Standards +1 603 851 2834 Media contact: Magda Bartoszewicz Director Corporate Brand and Communications, LGC Group +44 7408 850 514

CHEManager
Sep 12th, 2025
LGC Opens $100 Million Pharma Synthesis Center in Canada

LGC Group has inaugurated a CAD$100 million (€61.5 million) Organic Chemistry Synthesis Centre of Excellence in Vaughan, canada, significantly expanding global capacity for advanced research chemicals to support the pharmaceutical and life sciences sectors.

GBJ Plastering
Apr 15th, 2025
Ensuring Precision in Analysis: Graham B Jackson Pty Ltd Supply of LGC Certified Reference Materials

Graham B Jackson Pty Ltd (GBJPL), an Australian leader in reference materials, partners with the globally renowned LGC Group to supply high-quality CRMs to laboratories across the country.

Health Technology Insights
Apr 4th, 2025
Laboratory Proficiency Testing Market to Reach $2.1 Billion by 2030

For example, LGC Group introduced a proficiency testing (PT) service in April 2020 that uses nucleic acid amplification testing to identify SARS-CoV-2 (COVID-19).